期刊文献+

群体药代动力学研究进展 被引量:5

Progress in search for population pharmacokinetics
原文传递
导出
摘要 群体药代动力学(PK)用统计学和动力学原理,对不同的人群定量计算其PK参数,并描述其个体间和个体内变异的特征以及来源。近年来其受到越来越多的重视,本文对群体PK的原理及应用进行了综述。 Population pharmacokinetics(PK) , based on the principle of statistics and PK, estimates a given population's pharmacokinetic characteristics and their variability, describes the source of inter/intra - individual variability, evaluates the impacts of eovariables, and helps us to understand the in vivo behavior of drug profoundly. There is an increasing focus on the population PK, because of its' powerful analysis ability. This article reviewed the principle and application of population PK.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2013年第1期73-75,共3页 The Chinese Journal of Clinical Pharmacology
关键词 群体药代动力学 非线性混合效应模型 治疗药物监测 population pharmacokinetics : nonlinear mixed - effects model: therapeutic drug monitoring
  • 相关文献

参考文献14

  • 1Center for Drug Evaluation Research,US.Department of Health and Human Services,Food and Drug Administration. Guidance for industry:population pharmacokinetics:Draft Guidance[EB/OL].http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072137.pdf,2012.
  • 2Martin-Jimenez T,Riviere JE. Populaiton pharmacokinetics in veterinary medicine:potential use for therapeutic drug monitoring and prediction of tissue residues[J].Journal of Veterinary Pharmacology and Therapeutics,1998.167-189.
  • 3魏树礼;张强.生物药剂学与药物动力学[M]北京:北京大学医学出版社,2007238-271.
  • 4Adams CP,Brantner VV. Estimating the cost of new drug development:is it really 802 million dollars[J].Health Affairs,2006.420-428.
  • 5Kuester K,Kovar A,Lupfert C. Population pharmacokinetic data analysis of three phase Ⅰ studies of matuzumab,a humanised anti-EGFR monoclonal antibody in clinical cancer development[J].Brithish J Cancer,2008.900-906.
  • 6Wolchok J,Neyns B,Linette G. Lpilimumab monotherapy in patients with pretreated advanced melanoma:a randomised,double-blind,multicentre,phase 2,dose-ranging study[J].Lancet Oncology,2010.155-164.
  • 7Dirks NL,Nolting A,Kovar A. Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck[J].Journal of Clinical Pharmacology,2008.267-278.
  • 8Latz JE,Chaudhary A,Ghosh A. Population pharmacokinetic analysis of ten phase Ⅱ clinical trials of pemetrexed in cancer patients[J].Cancer Chemotherapy and Pharmacology,2006.401-411.
  • 9Veyrat-follet C,Vivier N,Trellu M. The pharmacokinetics of idraparinux,a long-acting indirect factor Xa inhibitor:population pharmacokinetic analysis from phase Ⅲ clinical trials[J].J Thormb Haemost,2009.559-565.
  • 10Gibiansky E,Zhang J,Williams D. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura[J].Journal of Clinical Pharmacology,2011.842-856.

二级参考文献12

  • 1杨丽华,卢新天,卢炜,吴克华,华瑛,赵卫红.大剂量甲氨喋呤在急性白血病患儿体内的群体药动学[J].中国药学杂志,2005,40(13):1007-1012. 被引量:25
  • 2Borsi J,Moe PJ.Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children[J].Cancer,1987,60:3020.
  • 3Wall AM,Gajjar A,Link A,et al.Individualyzed methotrexate dosing in children with relapsed acute lymphoblastic Leukemia[J].Leukemia,2000,14:221.
  • 4Evans WE,Crom WR,Stewart LCV,et al.Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukemia[J].Lancet,1984,1(8373):359.
  • 5Evans WE,Crom WR,Abromowitch M,et al.Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia[J].N Engl J Med,1986,314:471.
  • 6Borsi JD,Moe PJ.Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children[J].Cancer,1987,60:3020.
  • 7Masson E,Relling MV,Synold TW,et al.Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo.A rationale for high-dose methotrexate[J].J Clin Invest,1996,97:73.
  • 8Wolfrom C,Hartmann R,Fengler R,et al.Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia[J].J Clin Oncol,1993,11:827.
  • 9Galpin AJ,Schuetz JD,Masson E,et al.Differences in folypolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts[J].Molecular Phamacology,1997,52:155.
  • 10Feickert HJ,Bettoni M,Schrappe,A Reiter,et al.Event-free survival of children with T-cell acute lymphoblastic leukemia after introduction of high dose methotrexate in multicenter trial ALL-BFM 86[J].Proc Am Soc Clin Oncol Annu Meet,1993,12:317.

共引文献15

同被引文献38

  • 1史庆华.影响因子评价专业学术期刊的科学性与局限性[J].现代情报,2006,26(1):35-36. 被引量:68
  • 2黎铁立,常燕群.126例癫痫患儿丙戊酸钠血药浓度监测结果分析[J].国际医药卫生导报,2006,12(18):12-14. 被引量:8
  • 3陈冠初.文献计量学与非文献计量学在期刊评价中的应用[J].编辑学报,2006,18(6):472-474. 被引量:20
  • 4裴发光,胡永狮.卡马西平治疗儿童癫痫的血药浓度观察[J].临床和实验医学杂志,2007,6(3):77-78. 被引量:11
  • 5Tanaka J,Kasai H,Shimizu K. Population pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients,adult patients,and healthy volunteers[J].{H}EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY,2013,(03):489-497.
  • 6Hennig S,Standing JF,Staatz CE. Population Pharmacokinetics of Tobramycin in Patients With and Without Cystic Fibrosis[J].{H}Clinical Pharmacokinetics,2013,(04):289-301.
  • 7Würthwein G,Cornely OA,Trame MN. Population Pharmacokinetics of Escalating Doses of Caspofungin in a Phase II Study of Patients with Invasive Aspergil osis[J].{H}Antimicrobial Agents and Chemotherapy,2013,(04):1664-1671.
  • 8Food and Drug Administration. Center for Drug Evaluation and Research(CDER). Center for Biologics Evaluation and Research(CBER). Guidance for industry Populaiton Pharmacokientics[EB/OL].http://www.fda.gov/downloads/scienceresearch/specialtopics/womenshealthresearch/ucm133184.pdf,2013.
  • 9Food and Drug Administration. Center for Drug Evaluation and Research(CDER). Center for Biologics Evaluation and Research(CBER). Guidance for Industry Pharmacokinetics in Patients with Impaired Hepatic Function:Study Design, Data Analysis, and Impact on Dosing and Labeling[EB/OL].http:/www.fda.gov/downloads/drugs/guidancecomplianceregulatoryi nformation/guidances/ucm072123.pdf,2013.
  • 10Lindbom L,Ribbing J,Jonsson EN. Perl-speaks-NONMEM(PsN)--a Perl module for NONMEM related programming[J].{H}Computer Methods and Programs in Biomedicine,2004,(02):85-94.

引证文献5

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部